Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2004

View Archived Issues

GammaCan develops anticancer immunotherapy based on IVIg

Alternative treatment for cholestatic liver disease

European approval for Pegasys for HCV patients with normal ALT levels

Phase II study investigates Racivir for HIV

MannKind plans phase III for Technosphere Insulin System

DeveloGen receives R&D funding for diabetic complications efforts

Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos

Mid-term management plan for Astellas

Thelin receives orphan drug designation

Orphan drug designation for CR-002 in IgA nephropathy

Canadian HIV Trials Network lends support to phase I/II study of IR-103

HER-2 Protein AutoVac breast cancer vaccine enters phase II

Sumitomo's SMP-797 shows promise as a novel hypolipidemic drug

Selenite sodium reduces radiation-associated diarrhea in uterine cancer patients

Orally available TGF-beta inhibitor prevents myocardial fibrosis in transgenic mouse model

Non-nucleoside reverse transcriptase inhibitors described by Roche Bioscience

Sankyo scientists test a series of oligosaccharides

Azetidinone derivatives described in patent literature

Guanidine derivative NPFF receptor antagonists emerge from Actelion research

Protein kinase modulators described in a Sugen patent

Novartis discloses antitumor agents

Methadone formulations for parenteral use

Antitumor efficacy of PR-350 plus intraoperative radiotherapy in pancreatic cancer

A specific cancer vaccine increases survival of patients with advanced NSCLC

Promising P-selectin antagonist for the treatment of atherosclerosis and vascular injury

Phase I data on the antiviral effects and safety of remofovir in hepatitis B patients

Update on the effects and safety of a tenofovir/emtricitabine combination in HIV-infected patients

Full alpha7 nicotinic receptor agonist may improve cognitive impairments in schizophrenia

Albuferon reduces viral load of patients with chronic HCV infection

New thiadiazinone oxazolidinones show greater potency against Gram-positive and -negative pathogens

Rho kinase inhibitor prevents macrophage infiltration in cardiac and renal injury models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...